Search

everythinglearnresearchcommunity

for

Search:↓

Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.

Some drugs linked to growth hormones may increase the chance of hair loss in women.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Adding a second method to PROTACs could improve cancer treatment.

Promising cancer treatments were found, but the manufacturer closed.

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

Nano-PROTACs could improve drug targeting and delivery by using nanotechnology.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

Provenge extends prostate cancer survival by about 4 months.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Smart nano-PROTACs improve cancer treatment by targeting proteins more precisely and reducing side effects.

Triptolide effectively and safely reduces actinic keratosis lesions in mice.

Talquetamab may cause hair loss and skin issues.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.